Overview

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).
Phase:
Phase 4
Details
Lead Sponsor:
Seoul St. Mary's Hospital
Collaborator:
GlaxoSmithKline
Treatments:
Rosiglitazone
Thioctic Acid